Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Update

by · The Cerbat Gem

Daré Bioscience, Inc. (NASDAQ:DARE – Get Free Report) was the recipient of a large decrease in short interest in March. As of March 31st, there was short interest totalling 62,400 shares, a decrease of 28.6% from the March 15th total of 87,400 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 24,100 shares, the short-interest ratio is presently 2.6 days.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Daré Bioscience in a research report on Tuesday, April 1st.

View Our Latest Stock Report on Daré Bioscience

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of Daré Bioscience in the 4th quarter worth $52,000. Renaissance Technologies LLC increased its stake in Daré Bioscience by 6.7% in the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock worth $214,000 after purchasing an additional 4,300 shares in the last quarter. Geode Capital Management LLC raised its holdings in Daré Bioscience by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after buying an additional 3,593 shares during the period. Finally, AMH Equity Ltd lifted its stake in Daré Bioscience by 50.0% during the fourth quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 50,000 shares in the last quarter. Institutional investors own 6.70% of the company’s stock.

Daré Bioscience Stock Down 0.3 %

NASDAQ DARE traded down $0.01 on Friday, reaching $2.90. 5,764 shares of the stock traded hands, compared to its average volume of 44,288. Daré Bioscience has a 12 month low of $2.67 and a 12 month high of $7.56. The company has a market cap of $25.67 million, a price-to-earnings ratio of -4.91 and a beta of 1.34. The firm’s fifty day simple moving average is $2.98 and its 200 day simple moving average is $3.25.

Daré Bioscience (NASDAQ:DARE – Get Free Report) last issued its quarterly earnings results on Monday, March 31st. The biotechnology company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.02. The business had revenue of ($0.06) million during the quarter, compared to the consensus estimate of $1.00 million. As a group, equities research analysts forecast that Daré Bioscience will post -0.49 EPS for the current fiscal year.

Daré Bioscience Company Profile

(Get Free Report)

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.

Further Reading